All data are based on the daily closing price as of August 28, 2025
p
PeptiDream
4587.TSE
10.36 USD
-0.34
-3.18%
Overview
Last close
10.36 usd
Market cap
1.34B usd
52 week high
19.95 usd
52 week low
9.05 usd
Target price
23.21 usd
Valuation
P/E
N/A
Forward P/E
39.0625
Price/Sales
10.541
Price/Book Value
3.8085
Enterprise Value
1.29B usd
EV/Revenue
9.9242
EV/EBITDA
32.026
Key financials
Revenue TTM
129.74M usd
Gross Profit TTM
52.40M usd
EBITDA TTM
-27.77M usd
Earnings per Share
-0.26 usd
Dividend
N/A usd
Total assets
541.52M usd
Net debt
-108.03M usd
About
PeptiDream Inc., a biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics. The company develops its products based on its Peptide Discovery Platform System, a drug finding platform that enables the production of non-standard peptide libraries for the identification of potent and selective macrocyclic peptide candidates, which then can be developed into peptide-based, small molecule-based, peptide-drug conjugate, and multi-functional peptide conjugates -based therapeutics and diagnostics. Its development pipeline include PD-L1 indicated for oncology and currently under Ph1 clinical phase development stage; PD-L1 BMS-986229 indicated for oncology and currently under Ph1 clinical phase development stage; CD38 BHV-1100 + NK Cells indicated for multiple myeloma and currently under Ph1 clinical phase development stage; S2-protein PA-001 indicated for COVID-19 and currently under Ph1 clinical phase development stage; GhR AZP-3813 indicated for acromegaly/NET and currently under Ph1 clinical phase development stage; Glypican-3 indicated for liver cancer and currently under preclinical development stage; Myostatin indicated for DMD/muscle disorders and currently under preclinical development stage; TfR indicated for neuromuscular disorders and currently under preclinical development stage; c-Kit indicated for allergic condition and currently under preclinical development stage; c-Met currently under preclinical development stage; and HA-protein indicated for influenza and currently under preclinical development stage. It also involved in the research, development, manufacture, sale, export, and import of various radiopharmaceutical and radio diagnostic products. It has a collaboration with Novartis Pharma AG. PeptiDream Inc. was incorporated in 2006 and is based in Kawasaki, Japan.